Is Your Life Sciences Patent Enabled? U.S. Supreme Court Will Decide This Year
VirtualIn this year’s foray into patent law, the Supreme Court will decide whether Amgen’s patent that claims antibodies by functional antigen binding and does not disclose the full range of antibody sequences is invalid for not meeting the enablement requirements of Section 112(b). Join us for this webinar on Tuesday, March 14 where Procopio experts […]